仙琚制药(002332) - 2015 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2015 was CNY 2,480,246,153.64, representing a 0.39% increase compared to CNY 2,470,533,019.31 in 2014[20] - Net profit attributable to shareholders for 2015 was CNY 106,551,038.95, an increase of 87.93% from CNY 56,695,716.73 in 2014[20] - The net cash flow from operating activities increased by 40.93% to CNY 199,607,086.19 in 2015, up from CNY 141,638,736.64 in 2014[20] - Basic earnings per share for 2015 were CNY 0.20, an increase of 81.82% compared to CNY 0.11 in 2014[20] - Total assets at the end of 2015 were CNY 3,438,943,218.46, a 22.71% increase from CNY 2,802,557,106.99 at the end of 2014[20] - Net assets attributable to shareholders increased by 76.34% to CNY 2,140,207,332.50 at the end of 2015, compared to CNY 1,213,676,115.11 at the end of 2014[20] - The company reported a weighted average return on equity of 7.70% for 2015, up from 4.78% in 2014[20] - The net profit after deducting non-recurring gains and losses was CNY 93,328,404.12, an increase of 84.67% from CNY 50,537,704.34 in 2014[20] Revenue Breakdown - The total operating revenue for the year was 2,480,246,153.64 CNY, with quarterly revenues of 561,637,464.43 CNY in Q1, 619,663,681.44 CNY in Q2, 664,242,870.04 CNY in Q3, and 634,702,137.73 CNY in Q4[24] - The pharmaceutical segment contributed ¥2,468,484,234.21, accounting for 99.53% of total revenue, with a year-on-year growth of 0.91%[55] - The anesthetics and muscle relaxants segment saw a significant increase in revenue by 23.45%, reaching ¥273,812,181.68[55] - Domestic sales amounted to ¥1,995,616,984.03, which is 80.46% of total sales, reflecting a growth of 2.44% year-on-year[55] Investment and Financing - The company completed a non-public offering of 98,708,111 shares at ¥8.93 per share, raising a total of ¥88,146.34 million, netting ¥86,194.84 million after expenses[52] - The total cash inflow from financing activities was ¥2,195,546,635.24, reflecting a growth of 41.99% compared to the previous year[68] - The company raised a total of 88,146.34 million yuan through a non-public issuance of shares, with a net amount of 86,194.84 million yuan after deducting fees[79] - The total investment amount during the reporting period was 35,492,145.33 yuan, representing a significant increase of 617.09% compared to the previous year[72] Research and Development - Research and development investment amounted to ¥86,496,266.50, which is 3.49% of the operating revenue, showing a decrease of 2.16% compared to the previous year[67] - The company received clinical approval for four new drugs, including sodium omekraton and mometasone furoate aerosol[40] - The company holds 22 authorized patents, with four new invention patents granted during the reporting period[40] - The company is committed to developing non-steroidal drugs and expanding its product line, particularly in medical devices and diagnostic reagents[91] Market Strategy and Operations - The company has implemented internal reforms to enhance sales platforms and market expansion, resulting in improved sales strategies and increased market competitiveness[32] - The company has focused on optimizing production processes and improving product quality, leading to a decrease in raw material costs and an increase in gross profit margins[32] - The company aims to enhance its core competitiveness by focusing on the construction of "manufacturing and sales platforms" while expanding sales scale[91] - The company plans to optimize product structure and reduce costs through technological research and production management[92] Risk Management - The company has identified several risks including changes in industry policies, raw material price fluctuations, and R&D risks, which are detailed in the management discussion section[6] - Risks include fluctuations in raw material prices, rising management costs, and challenges in new drug development, which could impact profitability[102][103] - The company will monitor policy changes closely and adjust strategies accordingly to mitigate risks and enhance competitiveness[103] Dividend Policy - The company plans to distribute a cash dividend of CNY 1 per 10 shares to all shareholders, based on a total of 610,808,111 shares[6] - The net profit attributable to shareholders for 2015 was 106,551,038.95 yuan, resulting in a dividend payout ratio of 57.33%[112] - The total distributable profit at the end of 2015 was 234,182,080.25 yuan after accounting for the legal surplus reserve[115] - The company’s cash dividend policy has remained consistent without adjustments during the reporting period[109] Environmental and Social Responsibility - The company achieved a significant reduction in wastewater discharge from 1,500 tons to approximately 1,000 tons per day through pollution source reduction actions[158] - The company has established a wastewater treatment facility with a design capacity of 2,400 tons per day and an air pollution control facility with a capacity of 60,000 cubic meters per hour[158] - The company actively engages in social responsibility initiatives, supporting local education, culture, and health[156] - The company has implemented a comprehensive EHS management system, including 43 EHS target indicators, to ensure compliance with environmental regulations[159] Corporate Governance - The company appointed Tianjian Accounting Firm as the auditor, with an audit fee of RMB 1.802 million for the reporting period[126] - The company has a structured remuneration decision-making process based on performance assessments conducted by the board and the compensation committee[198] - The company has a diverse board with a mix of genders, including 3 female independent directors[200] - The management team includes experienced professionals with backgrounds in engineering and pharmaceuticals, enhancing the company's operational capabilities[196]